<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602430</url>
  </required_header>
  <id_info>
    <org_study_id>phCL 36</org_study_id>
    <nct_id>NCT03602430</nct_id>
  </id_info>
  <brief_title>Cholecalciferol on Hemodialysis Patients</brief_title>
  <official_title>Effect of Cholecalciferol on Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Screening the prevalence of vitamin D deficiency among Egyptian hemodialysis patients on
           a single center (Ain Shams University hospital).

        -  Assessing the effect of the native type of vitamin D (Cholecalciferol) on replenishing
           its deficiency via extra-renal vitamin D receptors (VDR), among Egyptian hemodialysis
           patients.

        -  Assessing the effect of cholecalciferol on vascular calcification among Egyptian
           hemodialysis patients.

        -  Assessing the effect of cholecalciferol on Blood pressure, parathyroid hormone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">September 28, 2018</completion_date>
  <primary_completion_date type="Actual">September 15, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D level</measure>
    <time_frame>3 months</time_frame>
    <description>Target serum Vitamin D level â‰¥ 30 ng/ml</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hemodialysis Complication</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Vascular Calcification</condition>
  <arm_group>
    <arm_group_label>Drug Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twenty-five patients will receive 200.000 IU/month native vitamin D; (Cholecalciferol) orally in addition to their standard treatment for 3 months period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>twenty-five patients will receive a placebo ampule with their standard treatment for 3 months period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Native vitamin D dose of 200IU to be given once per month to hemodialysis patients</description>
    <arm_group_label>Drug Group</arm_group_label>
    <other_name>Native vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Both sexes aged between 18-75 years

          2. Patients on HD greater than 3 months at least.

          3. Stable clinical condition (no hospitalization in the previous 3 months)

          4. Informed consent in accordance with the Declaration of Helsinki.

          5. PTH level between 150 - 800 pg/ml.

        Exclusion Criteria:

          1. Hypersensitivity to cholecalciferol.

          2. Participant in an another clinical trial within the past 4 weeks.

          3. Judged to be unsuitable as a subject by the attending physician.

          4. Pregnant or breastfeeding female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mona AlShahawey AlSayed Ghazy</investigator_full_name>
    <investigator_title>Assistant lecturer of Clinical Pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

